NINLARO (ixazomib), antineoplastic agent
Reason for request
Substantial clinical benefit in combination with lenalidomide and dexamethasone in the treatment of multiple myeloma for patients who have received at least one prior therapy and no clinical benefit demonstrated compared to the lenalidomide and dexamethasone combination
NINLARO has been granted marketing authorization (MA) in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
The results of a study with low robustness on primary endpoint (progression-free survival) do not show any clinical benefit from NINLARO combined with lenalidomide and dexamethasone compared to the lenalidomide and dexamethasone combination.
Improvement in actual benefit